An individualized Bayesian method for estimating genomic variants of hypertension

Md. Asad Rahman; Chunhui Cai; Dennis M. McNamara; Ying Ding; Gregory F. Cooper; Xinghua Lu; Jinling Liu

doi:10.1101/2022.06.25.22276897

Abstract

Background Genomic variants of disease are often discovered nowadays through population-based genome-wide association studies (GWAS). Identifying genomic variations potentially underlying a phenotype, such as hypertension, in an individual is important for designing personalized treatment; however, population-level models, such as GWAS, may not capture all of the important, individualized factors well. In addition, GWAS typically requires a large sample size to detect association of low-frequency genomic variants with sufficient power. Here, we report an individualized Bayesian inference (IBI) algorithm for estimating the genomic variants that influence complex traits such as hypertension at the level of an individual (e.g., a patient). By modeling at the level of the individual, IBI seeks to find genomic variants observed in the individual’s genome that provide a strong explanation of the phenotype observed in this individual.

Results We applied the IBI algorithm to the data from the Framingham Heart Study to explore genomic influences of hypertension. Among the top-ranking variants identified by IBI and GWAS, there is a significant number of shared variants (intersection); the unique variants identified only by IBI tend to have relatively lower minor allele frequency than those identified by GWAS. In addition, we observed that IBI discovered more individualized and diverse variants that explain the hypertension patients better than did GWAS. Furthermore, IBI found several well-known low-frequency variants as well as genes related to blood pressure that were missed by GWAS in the same cohort. Finally, IBI identified top-ranked variants that predicted hypertension better than did GWAS, according to the area under the ROC curve.

Conclusions The results provide support for IBI as a promising approach for complementing GWAS especially in detecting low-frequency genomic variants as well as learning personalized genomic variants of clinical traits and disease, such as the complex trait of hypertension, to help advance precision medicine.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was funded in part by the BioData Catalyst Fellowship award (0065304) from the National Institutes of Health, National Heart, Lung, and Blood Institute through the University of North Carolina at Chapel Hill, grant R01LM012011 from the National Institutes of Health, R01 MD009118 from the National Institute on Minority Health and Health Disparities (NIMHD).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of University of Missouri-Columbia gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes